港股异动 | 复宏汉霖(02696)早盘涨超5% 公司将汉斯状日本权益授权给卫材 交易总额约3.88亿美元

Core Viewpoint - The announcement of the licensing agreement for the anti-PD-1 monoclonal antibody H drug, Hansuzhu (SruLi monoclonal antibody), to Eisai has positively impacted the stock price of Fuhong Hanlin, reflecting investor confidence in the potential revenue from this partnership [1] Group 1: Financial Terms of the Agreement - Eisai will pay Fuhong Hanlin an upfront payment of $75 million [1] - Additional regulatory milestone payments could reach up to $80.01 million [1] - Sales milestone payments could total up to $233.3 million, along with a double-digit percentage royalty based on product sales [1] Group 2: Product Information - SruLi monoclonal antibody is an innovative anti-PD-1 monoclonal antibody developed by Fuhong Hanlin [1] - In China, SruLi has been approved for multiple indications, including squamous non-small cell lung cancer (sqNSCLC), extensive-stage small cell lung cancer (ES-SCLC), non-squamous non-small cell lung cancer (nsqNSCLC), and esophageal squamous cell carcinoma (ESCC) [1] - In the European Union, SruLi has been approved for the ES-SCLC indication and is the first anti-PD-1 monoclonal antibody approved for first-line treatment of ES-SCLC globally [1]